Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
NCT01513317 · Janssen Research & Development, LLC · PHASE2 · terminated · last registry update 2014-09-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was stopped after the interim analysis based on lack of sufficient efficacy. There were no safety concerns.” | – | Registry record, Janssen Research & Development, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-08-24Phase 3 first posted: GlaxoSmithKline, Sirukumab + Placebo to match sirukumab (NCT02531633)
- 2015-08-04Results posted on the registry: Janssen Research & Development, LLC, Siltuximab + Bortezomib (NCT00401843)
- 2015-06-19Results posted on the registry: M.D. Anderson Cancer Center, Lenalidomide + Bortezomib (NCT01531998)
- 2014-11-18Results posted on the registry: Janssen Research & Development, LLC, Siltuximab11 mg/kg + Siltuximab 8.3 mg/kg or 11 mg/kg (NCT00911859)
- 2014-08-20Results posted on the registry: Janssen Research & Development, LLC, Siltuximab + Placebo (NCT01024036)
- 2014-08-20Also stopped (terminated): Centocor, Inc., Mitoxantrone + Siltuximab (NCT00385827)
- 2014-06-12Results posted on the registry: Centocor, Inc., Mitoxantrone + Siltuximab (NCT00385827)
- 2014-05-19Also stopped (terminated): Janssen Pharmaceutical K.K., Siltuximab (NCT01309412)
- 2013-12-24Phase 3 first posted: Janssen Research & Development, LLC, adalimumab 40 mg + sirukumab 100 mg (NCT02019472)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision